ArticleJACC. Case reports2026
Development of Proteinuria in Patient With Solitary Kidney on Rosuvastatin.
Article in JACC. Case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHigh-dose rosuvastatin (40 mg) has been associated with transient proteinuria, particularly in patients with severe chronic kidney disease. CASE SUMMARY: We report a 59-year-old woman with a solitary kidney who developed proteinuria while on rosuvastatin 40 mg daily. The reduction of the dose to 10 mg daily led to complete resolution of proteinuria. DISCUSSION: The Food and Drug Administration recommendations advise a dose reduction of rosuvastatin to 10 mg in patients with severe chronic kidney disease, but no guidance exists for individuals with a solitary kidney and preserved renal function. This case suggests that these patients may be at risk of rosuvastatin-associated proteinuria and could benefit from lower doses. TAKE-HOME MESSAGES: Clinicians should use caution when prescribing high-dose rosuvastatin in patients with a solitary kidney. Further study is warranted to clarify whether solitary kidney status independently increases the risk of proteinuria.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.